FidoCure CEO Christina Lopes to Showcase World's First Portfolio of Canine Cancer Drugs at 2024 Animal Health Summit

FidoCure CEO Christina Lopes will present at the 2024 Animal Health Summit in Kansas City on August 26-27. The summit will showcase emerging companies and foster connections between innovators, investors, and industry leaders in animal health, nutrition, and technology. Attendees can also expect 1:1 business partnering opportunities, interactive experiences, and presentations from some of the world's leading minds in the field.

As part of the Emerging Company Presentations, Lopes will highlight FidoCure's patented approach to treating canine cancer. Using advanced genomic sequencing and AI-driven analysis, FidoCure has developed the world's first portfolio of precision medicines for dogs with cancer. This innovative method allows for personalized treatment plans that can significantly improve outcomes for our canine companions.

"We're excited to share FidoCure's mission with the animal health community," says Lopes. "Our goal is to increase access to lifesaving treatments for pet dogs with cancer.”

During her presentation, Lopes will discuss several key aspects of FidoCure's work:

1. The urgent need for better canine cancer treatments, with cancer being the leading cause of death in dogs over 10 years old.
2. FidoCure's unique approach to identifying human drugs that can be effectively applied to canine cancer treatment.
3. The company's clinical validation, with studies across over 2,000 canine cancer patients in 200 veterinary clinics.
4. How FidoCure's AI engine speeds up the identification of promising treatments, allowing for a substantial drug pipeline without traditional development time.
5. The potential for FidoCure's approach to significantly improve outcomes while managing side effects, making advanced cancer care more accessible for general practitioners and pet parents.

The Animal Health Summit has a track record of showcasing companies that go on to raise significant funding or secure important partnerships. Since its inception, emerging companies presenting at the summit have raised over half a billion dollars collectively, with many securing licensing agreements, distribution contracts, or being acquired.

For FidoCure, this presentation represents more than just an opportunity to share their progress. It's a chance to connect with potential partners and investors who can help accelerate their mission to improve the lives of dogs with cancer. As the animal health industry continues to evolve, FidoCure's participation underscores the growing importance of precision medicine in veterinary oncology. We look forward to sharing our vision for transforming canine cancer care and exploring new collaborations that can bring hope to more pets and their families.